Magnesium Bioresorbable Scaffold (Magmaris, Biotronik) is a device with promising outcomes at 24 months of follow up. Previous studies with first generation, everolimus-eluting Bioresorbable Vascular Scaffold (Absorb, Abbott) showed that very late restenosis seems to be attributed to pure intrascaffold tissue growth but very late. Magmaris very late restenosis has not been previously published, probably because of the 95% of resorption at 12 months. We present in-scaffold very late restenosis within Magmaris, with Optical Coherence Tomography, highlighting mechanism of degradation and in scaffold "neo-tissue" growth.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccd.28608DOI Listing

Publication Analysis

Top Keywords

late restenosis
12
magmaris late
8
magmaris
4
late in-scaffold
4
restenosis
4
in-scaffold restenosis
4
restenosis "black
4
"black boxes"
4
boxes" nightmare
4
nightmare back?
4

Similar Publications

Modification of polylactic acid (PLA) is a promising strategy for the next generation of bioresorbable vascular stent biomaterials. With this focus, FeMOFs nanoparticles was incorporated in PLA, and then post loading of carbon monoxide (CO) was performed by pressurization. It showed FeMOFs incorporation increased hydrophilicity of the surface and CO loading, and CO release was sustained at least for 3 days.

View Article and Find Full Text PDF

Baicalin-based composite coating for achieving biological multifunctionality of vascular stents.

J Control Release

January 2025

Institute of Biomedical Engineering, College of Medicine, Southwest Jiaotong University, Chengdu 610031, PR China. Electronic address:

Article Synopsis
  • Vascular stents are crucial for treating atherosclerosis and have reduced mortality through bare metal and drug-eluting options, but concerns like restenosis and thrombus formation persist.
  • Hyaluronic acid (HA) is often used to modify stent surfaces, but its effectiveness is limited due to degradation by reactive oxygen species (ROS) and enzymes, which can provoke inflammation and affect stent performance.
  • The study introduces a new coating using baicalin (BCL) to protect HA from degradation, offering enhanced endothelial cell support and greater stability, positioning this method as a promising advancement in stent technology.
View Article and Find Full Text PDF

Purpose: Takayasu arteritis (TAK) is a rare form of chronic vasculitis that is common in Asian female. As TAK predominantly affects young female with a longer life expectancy than those with atherosclerotic diseases, assessing the specific long-term outcomes of TAK treatment is important. Therefore, this study aimed to evaluate the long-term outcomes and post-procedural complications of surgical and endovascular treatment for TAK.

View Article and Find Full Text PDF

Background: Because of the limitations in new-generation drug-eluting stents (DES), treatments advocating for non-stents with a drug-coated balloon (DCB) is now of great interest. Here, we conducted a meta-analysis to testify whether a DCB was more effective and safer than a DES in treating de novo coronary artery disease (CAD).

Methods: We searched PubMed, Embase, Cochrane Library, and Web of Science to obtain high-quality trials comparing DCB with DES for the treatment of de novo CAD.

View Article and Find Full Text PDF

Background: Elective unprotected left main (ULM) percutaneous coronary intervention (PCI) has long-term mortality rates comparable to surgical revascularization, thanks to advances in drug-eluting stent (DES) design, improved PCI techniques, and frequent use of intravascular imaging. However, urgent PCI of ULM culprit lesions remains associated with high in-hospital mortality and unfavourable long-term outcomes, including DES restenosis and stent thrombosis (ST). This analysis aimed to examine the long-term outcomes and healing of DES implanted in ULM during primary PCI using high-resolution optical coherence tomography (OCT) imaging.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!